Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (348)	7/22/1999 1:14:00 AM
From: John Metcalf	Respond to of 399

Nice syllogism, Rick. And probably placed correctly-:) ARQL may have delivered about 30 compounds to partners, at least one of which were promised to enter the clinic in 1998. Yeah, right, so far in mid-99. I've seen nada. I sleep several hours each day, so if I an ArQule product advanced to the clinic, please tell me about it. SEPR has patents on versions of 60 drugs which are already on the market. Two of Sepracor's products, Xopenex and Allegra, are marketed. Sepracor has multiple clinical trials going, and more promised this year. What exactly was the comparison between these companies? Both in N. America? Both listed on NASD? Both in Massachusetts? Both CEO's like sushi? mutter, mutter, must be something....